EUVIMEDEUVIMED entdecken
Crossref

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis

Eric WFW Alton, David K Armstrong, Deborah Ashby, Katie J Bayfield, Diana Bilton, Emily V Bloomfield, A Christopher Boyd, June Brand, Ruaridh Buchan, Roberto Calcedo, Paula Carvelli, Mario Chan und 28 weitere

Efficacy and Mechanism Evaluation · 2016

DOI: 10.3310/eme03050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Efficacy and Mechanism Evaluation, 2016. Verfasst von Eric WFW Alton und 39 weiteren Autor:innen. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Efficacy and Mechanism Evaluation programme, Medical Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene leading to abnormal airway surface ion transport, chronic lung infections, inflammation and eventual respiratory failure. With the exception of the small-molecule potentiator, ivacaftor (Kalydeco ® , Vertex Pharmaceuticals, Boston, MA, USA), which is suitable for a small proportion of patients, there are no licensed therapies targeting the basic defect. The UK Cystic Fibrosis Gene Therapy Consortium has taken a cationic lipid-mediated CFTR gene therapy formulation through preclinical and clinical development.

Objective

To determine clinical efficacy of the formulation delivered to the airways over a period of 1 year in patients with CF.

Design

This was a randomised, double-blind, placebo-controlled Phase IIb trial of the CFTR gene–liposome complex pGM169/GL67A. Randomisation was performed via InForm™ version 4.6 (Phase Forward Incorporated, Oracle, CA, USA) and was 1 : 1, except for patients in the mechanistic subgroups (2 : 1). Allocation was blinded by masking nebuliser chambers. Settings Data were collected in the clinical and scientific sites and entered onto a trial-specific InForm, version 4.6 database.

Participants

Patients with CF aged ≥ 12 years with forced expiratory volume in the first second (FEV 1 ) between 50% and 90% predicted and any combination of CFTR mutations. The per-protocol group (≥ 9 doses) consisted of 54 patients receiving placebo (62 randomised) and 62 patients receiving gene therapy (78 randomised).

Interventions

Subjects received 5 ml of nebulised pGM169/G67A (active) or 0.9% saline (placebo) at 28 (±5)-day intervals over 1 year. Main outcome measures The primary end point was the relative change in percentage predicted FEV 1 over the 12-month period. A number of secondary clinical outcomes were assessed alongside safety measures: other spirometric values; lung clearance index (LCI) assessed by multibreath washout; structural disease on computed tomography (CT) scan; the Cystic Fibrosis Questionnaire – Revised (CFQ-R), a validated quality-of-life questionnaire; exercise capacity and monitoring; systemic and sputum inflammatory markers; and adverse events (AEs). A mechanistic study was performed in a subgroup in whom transgene deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) was measured alongside nasal and lower airway potential difference.

Results

There was a significant ( p = 0.046) treatment effect (TE) of 3.7% [95% confidence interval (CI) 0.1% to 7.3%] in the primary end point at 12 months and in secondary end points, including forced vital capacity (FVC) ( p = 0.031) and CT gas trapping ( p = 0.048). Other outcomes, although not reaching statistical significance, favoured active treatment. Effects were noted by 1 month and were irrespective of sex, age or CFTR mutation class. Subjects with a more severe baseline FEV 1 had a FEV 1 TE of 6.4% (95% CI 0.8% to 12.1%) and greater changes in many other secondary outcomes. However, the more mildly affected group also demonstrated benefits, particularly in small airway disease markers such as LCI. The active group showed a significantly ( p = 0.032) greater bronchial chloride secretory response. No difference in treatment-attributable AEs was seen between the placebo and active groups.

Conclusions

Monthly application of the pGM169/GL67A gene therapy formulation was associated with an improvement in lung function, other clinically relevant parameters and bronchial CFTR function, compared with placebo.

Limitations

Although encouraging, the improvement in FEV 1 was modest and was not accompanied by detectable improvement in patients’ quality of life. Future work Future work will focus on attempts to increase efficacy by increasing dose or frequency, the coadministration of a CFTR potentiator, or the use of modified viral vectors capable of repeated administration.

Trial registration

ClinicalTrials.gov NCT01621867. Funding This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research partnership.

Förderung

  • Efficacy and Mechanism Evaluation programme
  • Medical Research Council

Zitieren

APA

Alton, E. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, D., Bloomfield, E. V., Boyd, A. C., Brand, J., Buchan, R., Calcedo, R., Carvelli, P., Chan, M., Cheng, S. H., Collie, D. S., Cunningham, S., Davidson, H. E., Davies, G., Davies, J. C., Davies, L. A., …, & Jacob, J. (2016). A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation. https://doi.org/10.3310/eme03050

Vancouver

Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, et al. A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation. 2016. doi:10.3310/eme03050

BibTeX
@article{Alton2016,
  author = {Alton, Eric WFW and Armstrong, David K and Ashby, Deborah and Bayfield, Katie J and Bilton, Diana and Bloomfield, Emily V and Boyd, A Christopher and Brand, June and Buchan, Ruaridh and Calcedo, Roberto and Carvelli, Paula and Chan, Mario and Cheng, Seng H and Collie, David S and Cunningham, Steve and Davidson, Heather E and Davies, Gwyneth and Davies, Jane C and Davies, Lee A and Dewar, Maria H and Doherty, Ann and Donovan, Jackie and Dwyer, Natalie S and Elgmati, Hala I and Featherstone, Rosanna F and Gavino, Jemyr and Gea-Sorli, Sabrina and Geddes, Duncan M and Gibson, James SR and Gill, Deborah R and Greening, Andrew P and Griesenbach, Uta and Hansell, David M and Harman, Katharine and Higgins, Tracy E and Hodges, Samantha L and Hyde, Stephen C and Hyndman, Laura and Innes, J Alastair and Jacob, Joseph},
  title = {A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis},
  journal = {Efficacy and Mechanism Evaluation},
  year = {2016},
  doi = {10.3310/eme03050}
}
Kostenlos starten →